TY - JOUR
T1 - Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the ovary
AU - Okamoto, Aikou
AU - Glasspool, Rosalind M.
AU - Mabuchi, Seiji
AU - Matsumura, Noriomi
AU - Nomura, Hiroyuki
AU - Itamochi, Hiroaki
AU - Takano, Masashi
AU - Takano, Tadao
AU - Susumu, Nobuyuki
AU - Aoki, Daisuke
AU - Konishi, Ikuo
AU - Covens, Alan
AU - Ledermann, Jonathan
AU - Mezzazanica, Delia
AU - Steer, Christopher
AU - Millan, David
AU - Mcneish, Iain A.
AU - Pfisterer, Jacobus
AU - Kang, Sokbom
AU - Gladieff, Laurence
AU - Bryce, Jane
AU - Oza, Amit
PY - 2014/11
Y1 - 2014/11
N2 - Clear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than highgrade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/ carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/ JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration.
AB - Clear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than highgrade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/ carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/ JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration.
UR - http://www.scopus.com/inward/record.url?scp=84922377545&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922377545&partnerID=8YFLogxK
U2 - 10.1097/IGC.0000000000000289
DO - 10.1097/IGC.0000000000000289
M3 - Review article
C2 - 25341576
AN - SCOPUS:84922377545
VL - 24
SP - S20-S25
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
SN - 1048-891X
IS - 9
ER -